Pet biotech focus Akston specializes in veterinary protein therapeutics designed specifically for pets, presenting a focused market niche where selling points center on affordability and pet-family bonds.

Mid-market scale With 51-200 employees and reported revenue between 25M and 50M, Akston sits in a mid-market tier that can benefit from partnerships with larger biotech manufacturers for scale-up, contract manufacturing, or joint development.

Domestic footprint Headquartered in Beverly, MA, Akston’s U.S. location enables proximity to national veterinary networks and pet care distributors, supporting regional business development and faster service levels.

R&D to manufacturing End-to-end capability from design to manufacture of protein therapeutics provides opportunities to offer development services, process optimization, and contract manufacturing for other pet biotech ventures.

Affordability narrative A strategic emphasis on affordable therapies for pets can be leveraged to position sales approaches around value-based pricing, reimbursements, and partnerships with veterinary clinics and pet insurers seeking cost-efficient treatments.